Discovery of 2‐phenylquinazolines as potent Mycobacterium avium efflux pump inhibitors able to synergize with clarithromycin against clinical isolate
Archiv der Pharmazie · 2024
DOI: 10.1002/ardp.202400296 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Giada Cernicchi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department Pharmaceutical Sciences, Università degli Studi di Perugia, Perugia, Italy. Hauptthemen laut MEDLINE: Clarithromycin, Microbial Sensitivity Tests, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PNRR THE-Tuscany Health Ecosystem; Spoke 7-Innovating Translational Medicine-Subproject 5-Innovative models for management of infections caused by antibiotic-r…, European Union-NextGenerationEU under the Italian Ministry of University and Research (MUR) National Innovation Ecosystem grant ECS00000041-VITALITY-CUP J97G22….
Abstract (Originalsprache)
Nontuberculous mycobacteria (NTM), which include the Mycobacterium avium complex, are classified as difficult‐to‐treat pathogens due to their ability to quickly develop drug resistance against the most common antibiotics used to treat NTM infections. The overexpression of efflux pumps (EPs) was demonstrated to be a key mechanism of clarithromycin (CLA) resistance in NTM. Therefore, in this work, 24 compounds from an in‐house library, characterized by chemical diversity, were tested as potential NTM EP inhibitors (EPIs) against Mycobacterium smegmatis mc 2 155 and M. avium clinical isolates. Based on the acquired results, 12 novel analogs of the best derivatives 1b and 7b were designed and synthesized to improve the NTM EP inhibition activity. Among the second set of compounds, 13b emerged as the most potent NTM EPI. At a concentration of 4 µg/mL, it reduced the CLA minimum inhibitory concentration by 16‐fold against the clinical isolate M. avium 2373 overexpressing EPs as primary mechanism of CLA resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department Pharmaceutical Sciences, Università degli Studi di Perugia, Perugia, Italy.
- Department of Veterinary Medicine, University of Perugia, Perugia, Italy.
- Department of Biology, Università di Pisa, Pisa, Italy.
- Department of Translational Research and New Technologies in Medicine and Surgery, Università di Pisa, Pisa, Italy.
Förderung
- PNRR THE-Tuscany Health Ecosystem; Spoke 7-Innovating Translational Medicine-Subproject 5-Innovative models for management of infections caused by antibiotic-r…
- European Union-NextGenerationEU under the Italian Ministry of University and Research (MUR) National Innovation Ecosystem grant ECS00000041-VITALITY-CUP J97G22…
Zitieren
APA
Cernicchi, G., Rampacci, E., Massari, S., Manfroni, G., Barreca, M. L., Tabarrini, O., Cecchetti, V., Felicetti, T., Di Luca, M., Poma, N. V., Tavanti, A., Passamonti, F., Rindi, L., & Sabatini, S. (2024). Discovery of 2‐phenylquinazolines as potent Mycobacterium avium efflux pump inhibitors able to synergize with clarithromycin against clinical isolate. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400296
Vancouver
Cernicchi G, Rampacci E, Massari S, Manfroni G, Barreca ML, Tabarrini O, et al. Discovery of 2‐phenylquinazolines as potent Mycobacterium avium efflux pump inhibitors able to synergize with clarithromycin against clinical isolate. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202400296
BibTeX
@article{Cernicchi2024,
author = {Cernicchi, Giada and Rampacci, Elisa and Massari, Serena and Manfroni, Giuseppe and Barreca, Maria Letizia and Tabarrini, Oriana and Cecchetti, Violetta and Felicetti, Tommaso and Di Luca, Mariagrazia and Poma, Noemi Violeta and Tavanti, Arianna and Passamonti, Fabrizio and Rindi, Laura and Sabatini, Stefano},
title = {Discovery of 2‐phenylquinazolines as potent Mycobacterium avium efflux pump inhibitors able to synergize with clarithromycin against clinical isolate},
journal = {Archiv der Pharmazie},
year = {2024},
doi = {10.1002/ardp.202400296}
}
EUVIMED